Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies.

Autor:	Twait EL; Julius Center for Health Sciences and Primary Care (ELT, MK, WMMV, MIG), University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands; Amsterdam UMC, Location Vrije Universiteit (ELT), Department of General Practice, Amsterdam Public Health, Amsterdam Neuroscience, Amsterdam, The Netherlands., Kamarioti M; Julius Center for Health Sciences and Primary Care (ELT, MK, WMMV, MIG), University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands., Verberk IMW; Neurochemistry Laboratory (IMWV, CET), Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Teunissen CE; Neurochemistry Laboratory (IMWV, CET), Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Nooyens ACJ; National Institute for Public Health and the Environment (ACJN, WMMV), Bilthoven, The Netherlands., Monique Verschuren WM; Julius Center for Health Sciences and Primary Care (ELT, MK, WMMV, MIG), University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands; National Institute for Public Health and the Environment (ACJN, WMMV), Bilthoven, The Netherlands., Visser PJ; Alzheimer Center Amsterdam (PJV, JEFM, WMF), Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands; Department of Psychiatry and Neuropsychology (PJV), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, The Netherlands., Huisman M; Amsterdam UMC Location Vrije Universiteit Amsterdam (MH, AALK, WMF), Epidemiology and Data Science, Amsterdam, The Netherlands; Department of Sociology, Faculty of Social Sciences (MH), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health (MH, AALK), Ageing and Later Life, Amsterdam, The Netherlands., Kok AAL; Amsterdam UMC Location Vrije Universiteit Amsterdam (MH, AALK, WMF), Epidemiology and Data Science, Amsterdam, The Netherlands; Amsterdam Public Health (MH, AALK), Ageing and Later Life, Amsterdam, The Netherlands., Eline Slagboom P; Molecular Epidemiology (PES, MB, DV, NL), Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Beekman M; Molecular Epidemiology (PES, MB, DV, NL), Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Vojinovic D; Molecular Epidemiology (PES, MB, DV, NL), Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; Department of Epidemiology (DV, MAI, IKS, FJW), Erasmus University Medical Center, Rotterdam, Netherlands., Lakenberg N; Molecular Epidemiology (PES, MB, DV, NL), Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Arfan Ikram M; Department of Epidemiology (DV, MAI, IKS, FJW), Erasmus University Medical Center, Rotterdam, Netherlands; Harvard T.H. Chan School of Public Health (MAI), Boston, MA., Schuurmans IK; Department of Epidemiology (DV, MAI, IKS, FJW), Erasmus University Medical Center, Rotterdam, Netherlands., Wolters FJ; Department of Epidemiology (DV, MAI, IKS, FJW), Erasmus University Medical Center, Rotterdam, Netherlands; Department of Radiology & Nuclear Medicine (FJW), Erasmus MC, Rotterdam The Netherlands., Moonen JEF; Alzheimer Center Amsterdam (PJV, JEFM, WMF), Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands., Gerritsen L; Department of Psychology (LG) Utrecht University, Utrecht, The Netherlands., van der Flier WM; Alzheimer Center Amsterdam (PJV, JEFM, WMF), Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands; Amsterdam UMC Location Vrije Universiteit Amsterdam (MH, AALK, WMF), Epidemiology and Data Science, Amsterdam, The Netherlands., Geerlings MI; Julius Center for Health Sciences and Primary Care (ELT, MK, WMMV, MIG), University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands; Amsterdam UMC (MIG), Location University of Amsterdam, Department of General Practice, Amsterdam Public Health, Amsterdam Neuroscience, Amsterdam, The Netherlands. Electronic address: m.i.geerlings@amsterdamumc.nl.
Jazyk:	angličtina
Zdroj:	The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry [Am J Geriatr Psychiatry] 2024 Sep; Vol. 32 (9), pp. 1141-1153. Date of Electronic Publication: 2024 Mar 11.
DOI:	10.1016/j.jagp.2024.03.004
Abstrakt:	Background: Depressive symptoms are associated with an increased risk of Alzheimer's disease (AD). There has been a recent emergence in plasma biomarkers for AD pathophysiology, such as amyloid-beta (Aβ) and phosphorylated tau (p-tau), as well as for axonal damage (neurofilament light, NfL) and astrocytic activation (glial fibrillary acidic protein, GFAP). Hypothesizing that depressive symptoms may occur along the AD process, we investigated associations between plasma biomarkers of AD with depressive symptoms in individuals without dementia. Methods: A two-stage meta-analysis was performed on 2 clinic-based and 6 population-based cohorts (N = 7210) as part of the Netherlands Consortium of Dementia Cohorts. Plasma markers (Aβ42/40, p-tau181, NfL, and GFAP) were measured using Single Molecular Array (Simoa; Quanterix) assays. Depressive symptoms were measured with validated questionnaires. We estimated the cross-sectional association of each standardized plasma marker (determinants) with standardized depressive symptoms (outcome) using linear regressions, correcting for age, sex, education, and APOE ε4 allele presence, as well as subgrouping by sex and APOE ε4 allele. Effect estimates were entered into a random-effects meta-analysis. Results: Mean age of participants was 71 years. The prevalence of clinically relevant depressive symptoms ranged from 1% to 22%. None of the plasma markers were associated with depressive symptoms in the meta-analyses. However, NfL was associated with depressive symptoms only in APOE ε4 carriers (β 0.11; 95% CI: 0.05-0.17). Conclusions: Late-life depressive symptoms did not show an association to plasma biomarkers of AD pathology. However, in APOE ε4 allele carriers, a more profound role of neurodegeneration was suggested with depressive symptoms. Competing Interests: DISCLOSURES No disclosures to report. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu